8-K: BioAtla Secures $9.2 Million in Registered Direct Offering to Advance Clinical Programs

BioAtla, Inc. has announced a registered direct offering expected to generate $9.2 million to fund its mid-stage clinical programs.

Summary

• BioAtla, Inc. entered into a securities purchase agreement on December 19, 2024, for a registered direct offering.
• The offering includes 9,679,158 shares of common stock and warrants to purchase an equal number of shares.
• The combined offering price is $0.9520 per share and accompanying warrant.
• The warrants are exercisable six months after issuance at $1.19 per share and expire in 5.5 years.
• The company expects to receive gross proceeds of approximately $9.2 million before deducting fees and expenses.
• The net proceeds will be used to fund research and development, including key inflection points for its T-Cell Engager (TCE) and Antibody Drug Conjugate (ADC) programs.
• Specifically, the funds will support BA3182 Phase 1 dose escalation data (expected 2Q25) and Phase 2 expansion data (expected 1H26), and mecbotamab vedotin Phase 2B data in mKRAS NSCLC (expected 1H26).
• The offering is expected to close on or about December 20, 2024, subject to customary closing conditions.
• Tungsten Advisors acted as the sole placement agent for the offering.

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive. The company is securing necessary funding for its clinical programs, which is a positive step. However, the offering involves dilution and the offering price is below the warrant exercise price, which are potential negatives.

Positives

• The capital raise provides funding to advance key clinical programs to important data readouts.
• The company has secured funding to support partnering activities and for working capital.
• The offering is structured with warrants that could provide additional capital if exercised.
• The company has a clear plan for the use of proceeds, focusing on research and development.

Negatives

• The offering involves the issuance of a significant number of new shares, which could dilute existing shareholders.
• The warrants, if exercised, could further dilute existing shareholders.
• The offering price of $0.9520 per share and warrant is below the warrant exercise price of $1.19, which may indicate a lower valuation.
• The company is relying on additional funding to reach key inflection points for its clinical programs.

Risks

• The company's clinical programs may not achieve the expected results or meet the anticipated timelines.
• The company may not be able to secure partnerships for its programs.
• The company may need to raise additional capital in the future if the current funding is insufficient.
• The market price of the company's stock could be negatively impacted by the offering and potential dilution.

Future Outlook

The company intends to use the net proceeds to fund its research and development efforts, including to reach several key inflection points for its mid-stage clinical T-Cell Engager (TCE) and Antibody Drug Conjugate (ADC) programs. The company expects data readouts for BA3182 in 2Q25 and 1H26, and for mecbotamab vedotin in 1H26.

Management Comments

• The company intends to use the net proceeds to be received by it in the offering, along with its existing cash and cash equivalents, to fund its research and development efforts.
• The company aims to reach several key inflection points for its mid-stage clinical T-Cell Engager (TCE) and Antibody Drug Conjugate (ADC) programs.

Industry Context

This capital raise is typical for a clinical-stage biotechnology company seeking to advance its drug development programs. The focus on T-Cell Engager and Antibody Drug Conjugate programs aligns with current trends in cancer therapeutics.

Comparison to Industry Standards

• The offering structure, combining shares and warrants, is a common method for raising capital in the biotech sector, particularly for companies with ongoing clinical trials.
• The use of proceeds for advancing clinical programs is standard practice for companies at this stage of development.
• The expected data readouts in 2025 and 2026 are typical timelines for mid-stage clinical trials.
• Comparable companies raising capital at this stage include Xencor, Inc. which recently raised $300 million in a public offering, and IGM Biosciences, Inc. which raised $200 million in a private placement. BioAtla's raise is significantly smaller, reflecting its current stage and valuation.

Stakeholder Impact

• Shareholders will experience dilution due to the issuance of new shares.
• Employees will benefit from the continued funding of research and development.
• Potential partners may be more interested in the company due to the progress of its clinical programs.
• Creditors may view the company more favorably due to the increased financial stability.

Next Steps

• The company will close the offering on or about December 20, 2024.
• The company will use the proceeds to advance its clinical programs and support partnering activities.
• The company will continue to monitor and report on the progress of its clinical trials.
• The company will seek to achieve key data readouts for its clinical programs in 2025 and 2026.

Key Dates

Keywords

registered direct offering, common stock, warrants, clinical programs, T-Cell Engager, Antibody Drug Conjugate, BA3182, mecbotamab vedotin, capital raise, biotechnology